TABLE 2.
Plasma HCV RNA values for subjects in this study
| Patient no. | Dose (mg/kg) | Plasma HCV RNA level (log10 RNA molecules/ml) at:
|
|||||
|---|---|---|---|---|---|---|---|
| Baselinea | Day 7 | Day 14 | Day 28 | Day 42 | Day 56 | ||
| 1 | 0.05 | 7.62 | 7.68 | 7.73 | 7.79 | 7.65 | 7.27 |
| 2 | 0.05 | 7.29 | 7.73 | 7.83 | 7.43 | 7.62 | 7.62 |
| 3 | 0.05 | 8.30 | 8.20 | 8.21 | 8.50 | 8.61 | 8.48 |
| 4 | 0.05 | 6.99 | 7.19 | 7.46 | 7.67 | 7.40 | 7.24 |
| 5 | 0.05 | 7.68 | 7.50 | 7.60 | 8.42 | 8.10 | 6.33b |
| 6 | 0.05 | 6.35 | 6.55 | 7.11 | 6.42 | 6.57 | 6.98 |
| 7 | 0.05 | 7.12 | 7.18 | 7.03 | 7.38 | 7.13 | 7.35 |
| 8 | 0.05 | 5.17 | 5.55 | 5.31 | 5.31 | 5.36 | 5.38 |
| 9c | 0.05 | 7.31 | 7.03 | 7.02 | 7.45c | ||
| 10 | 0.05 | 7.85 | 7.98 | 7.74 | 7.99 | 8.20 | 7.71 |
| 11 | 0.05 | 7.87 | 7.51 | 8.03 | 8.31 | 8.03 | 8.30 |
| 12 | 0.05 | 6.53 | 7.51 | 7.01 | 7.24 | 7.24 | |
| Mean | 7.17 | 7.30 | 7.34 | 7.49 | 7.40 | 7.26 | |
| SD | 0.84 | 0.70 | 0.76 | 0.90 | 0.91 | 0.86 | |
| 13 | 0.10 | 7.60 | 7.52 | 7.42 | 7.72 | 7.72 | 7.84 |
| 14 | 0.10 | 8.04 | 8.09 | 8.16 | 7.75 | 7.60 | 7.05 |
| 15 | 0.10 | 8.07 | 8.05 | 8.36 | 7.25 | 7.78 | 8.48 |
| 16 | 0.10 | 7.45 | 7.58 | 7.51 | 7.19 | 7.75 | 7.51 |
| 17 | 0.10 | 8.05 | 7.60 | 7.36 | 7.40 | 7.61 | 7.35d |
| 18 | 0.10 | 6.97 | 6.88 | 7.11 | 6.99 | 7.33 | 6.76 |
| 19 | 0.10 | 7.05 | 6.25 | 7.28 | 6.67 | 6.40 | 6.50 |
| Mean | 7.60 | 7.42 | 7.60 | 7.28 | 7.46 | 7.36 | |
| SD | 0.47 | 0.66 | 0.47 | 0.39 | 0.49 | 0.67 | |
a
Plasma HCV RNA results obtained at the prescreening visit (within 7 days of baseline) and on the day of treatment initiation were averaged for the baseline plasma HCV RNA value.
b
Patient 5 did not complete 56 days of hypericin. The last day of treatment was day 42.
c
Patient 9 did not complete 56 days of hypericin. The last day of treatment was day 11.
d
Patient 17 did not complete 56 days of hypericin. The last day of treatment was day 30, and the value shown here is the day 28 value.